Home › Trial NCT04887506
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
- Trial IDNCT04887506
- StatusCompleted
- PhasePhase 3
- Study typeInterventional
- SponsorTavanta Therapeutics
- Enrollment107
- Start date2021-05-05
- ConditionsMetastatic Castration-resistant Prostate Cancer · Metastatic Castration-sensitive Prostate Cancer · Metastatic Prostate Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.